Joint Commissioner of Police (CP), Sharad Singhal said that in the first phase about 1.5 lakh square kilometres of illegal encroachment was cleared and further said that the public was cooperating.
Gulf Pharmaceutical Industries (Julphar) plans to invest AED 300 million over the next five years to expand its manufacturing capabilities and localise advanced technologies. CEO Basel Ziyadeh announced the move during the "Make it in the Emirates 2025" event, reinforcing Julphar's role in b
The Israeli Defence Forces (IDF) provided a comprehensive overview into its latest operations against Hamas. IDF Spokesperson Lt Col Nadav Shoshani listed down the major objectives of Operation Gideon's Chariot through a video message on Monday.
Generic drug companies in India are not expected to be affected by US President Donald Trump's new order to bring the prices for prescription (Rx) drugs in line with other developed nations, says a report by HDFC Securities.
Bollywood superstar Aamir Khan and ace director Rajkumar Hirani are set to reunite after 11 years for the biopic of Dadasaheb Phalke, the father of Indian cinema.
Japanese electronics giant TDK Corporation is set to deepen its footprint in India with the launch of its sixth manufacturing facility, underscoring the company's strategic vision to align with India's rapid economic growth and evolving technology landscape.
The Haryana 112 Emergency Response Support System (ERSS) has marked substantial progress in its emergency response efficiency, as revealed in the latest performance update for April 2025.
New Delhi [India], May 13: SVKM's NMIMS, one of India's leading academic institutions, successfully hosted its 22nd Convocation Ceremony, celebrating the academic achievements of students from its MBA, MBA (Human Resources), MBA (Pharmaceutical Management) programs
India's generics medicine industry is unlikely to be impacted by President Donald Trump's move to slash drug prices in the US drastically, said Sudarshan Jain, Secretary General, Indian Pharmaceutical Alliance (IPA).
Indian pharmaceutical major Piramal Pharma Limited has announced a USD 90 million investment plan towards expanding two of the Company's US facilities.